This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Davis, M. Articles by Woolf, A. Search for Related Content PubMed PubMed Citation Articles by Davis, M. Articles by Woolf, A. Social Bookmarking                         What's this?

Role of antimalarials in rheumatoid arthritis — the British experience

Duke of Cornwall Rheumatology Unit, Truro, Cornwall, UK

AD Woolf

Duke of Cornwall Rheumatology Unit, Truro, Cornwall, UK

Antimalarials have been used to treat rheumatoid arthritis (RA) for over 40 years, the first report of suggestive efficacy being published in 19511. Over the years they have become part of the established treatment of RA being one of a category of drugs referred to as disease modifying anti-rheumatic drugs (DMARDs). The onset of action with antimalarials is slow. Most patients use these drugs in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics. This article reviews the evidence for the efficacy of antimalarials, their place in comparison to other DMARDs and comments on the current use in RA as perceived in British rheumatology.

Key Words: rheumatoid arthritis • antimalarials • efficacy • toxicity

Lupus, Vol. 5, No. 1 suppl, S37-S40 (1996)
DOI: 10.1177/096120339600500109


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?